Trials / Unknown
UnknownNCT03598959
Tofacitinib Combined With Chidamide in R/R ENKTCL
Phase I/II Study of Safety and Efficacy of Tofacitinib Combined With Chidamide in Patients With Relapsed and Refractory Extranodal Natural Killer/T Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tofacitinib | orally 10 mg daily |
| DRUG | chidamide | orally 20 mg twice weekly |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2019-12-31
- Completion
- 2021-12-31
- First posted
- 2018-07-26
- Last updated
- 2018-07-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03598959. Inclusion in this directory is not an endorsement.